The number of medical cannabis prescriptions issued under Australia’s special access system continues to grow.
In March, 9,959 SAS Category B marijuana prescriptions were issued, two and a half times as many as a year ago, the Australian Therapeutic Goods Administration said this week.
The 8,057 registrations in February were the previous record. An average of 5,000 prescriptions have been prescribed over the past 12 months.
Since the medical marijuana access scheme was introduced in 2016, over 100,000 prescriptions have been prescribed to an unknown number of patients. (The TGA states that it receives unidentified applications and cannot assign them to individual patients.)
These numbers don’t even include prescriptions written by “authorized prescribers” who often prescribe a large amount of cannabis and don’t need to get TGA approval for every single script.
At the end of February there were 215 “authorized prescribers”, compared to 179 at the beginning of the year and only 29 in December 2019.
Under the rules of the TGA, patients can access marijuana to treat cancer and non-cancer pain. Anorexia and waste related to chronic diseases; Chemotherapy-induced nauseua; and other conditions.
Elsewhere this week, in North America, law was passed in both Connecticut and Mexico.
Of the 36 companies in the ASX cannabis sector, 15 gained ground and 11 lost over the past week.
The biggest winner was Eve Investments, an increase of 16.7 percent to 0.7c without news.
MGC Pharmaceuticals (ASX: MXC) was the best performer since the beginning of the year, rising 180 percent to 7c.
|code||Surname||price||% Wk||YTD% return||6 months% ret||Market capitalization|
|APH||AP hemp||41||-4.7||7th||141.2||$ 32,049,307|
|AGH||Althea Group||51||5.2||7.5||8.5||$ 131,186,770|
|AC8||Auscann Grp St.||13.5||-3.6||-6||-6.7||$ 61,676,595|
|BDA||Bod Australia||52.5||11.7||3.5||34.2||$ 52,382,840|
|BOT||Botanix Pharma||9.3||-5.1||-3.2||-6.0||$ 90,502,213|
|CGB||Can not be global||0.8||0.0||0.1||100.0||$ 41,114,042|
|CAN||Can’t group||55||1.9||-4||32.5||$ 152,814,450|
|CPH||Creso Pharma||20.5||2.5||2.5||528.8||$ 214,893,089|
|CAU||Cronos Australia||12th||0.0||-1||50.0||$ 6,807,500|
|DTZ||Dotz Nano||36.5||7.4||12.5||23.7||$ 139,261,480|
|ECS||ECS Botanics Holding||5.1||4.1||1.2||117.4||$ 29,507,665|
|EVE||EVE investments||0.7||16.7||-0.2||-40.0||$ 23,058,851|
|EOF||Eco fiber||119||-0.8||-71.5||-50.4||$ 400,456,436|
|EXL||Elixinol Global||18.5||2.8||1||19.4||$ 58,216,430|
|EN1||Engage: Bdr||0.6||0.0||0||9.1||$ 14,691,429|
|EPN||Epsilon Healthcare||21.5||7.5||-2||-8.5||$ 39,995,959|
|THE||Esense Lab||1.8||0.0||0||0.0||$ 9,180,684|
|IDT||IDT Australia||36.5||-18.0||18th||128.1||$ 100,900,659|
|IHL||Incannex Healthcare||21.5||4.9||6.5||144.2||$ 227,575,256|
|LSH||Health as a habitat||10.5||-8.7||2.8||112.1||$ 15,667,427|
|LGP||Little Green Pharma||72.5||3.6||16||151.7||$ 95,932,737|
|LV1||Live Verdure||25th||-3.8||6th||$ 10,607,222|
|MMY||MMJ Group Hlds||11||-4.3||-1.5||27.8||$ 25,294,938|
|MDC||Medlab Clinical||26.5||10.4||2.5||36.8||$ 82,013,915|
|MXC||Mgc Pharmaceuticals||7th||12.9||4.5||191.7||155,003,662 USD|
|MRG||Murray River Grp||24.5||-7.5||-30.5||-57.4||$ 11,028,786|
|NTI||Neurotech Intl||7.6||0.0||3.1||442.9||$ 47,934,074|
|DUDE||Pharmaceutical ball||48.5||-2.0||-28.5||-30.1||$ 80,147,016|
|ROO||Sustainable roots||1.9||0.0||-0.2||-20.8||$ 10,255,895|
|RGI||Roto-Gro Intl||4.9||-9.3||-1.4||8.9||$ 12,571,092|
|SCU||Stemcell United||2.2||0.0||0.3||100.0||$ 18,487,054|
|SOUTH||Suda Pharmaceuticals||4.6||0.0||0.6||12.5||$ 16,540,208|
|WOA||Wide open agriculture||72.5||4.3||-16.5||-27.6||$ 65,806,600|
|YPB||YPB group||0.35||0.0||0.15||-12.5||$ 14,975,462|
|ZLD||Zelira Therapeutics||6.1||1.7||-3.1||-12.9||72,609,701 USD|
Get the latest Stockhead news delivered to your inbox for free.
It’s free. Log out whenever you want.